2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons

Dyslipidemia: Statin Benefit Groups, Non-Statin Therapies, and Lipid Optimization

Atherosclerotic Cardiovascular Disease (ASCVD) is the leading cause of morbidity and mortality in the United States. Serum Low-Density Lipoprotein Cholesterol (LDL-C) is a causal, modifiable risk factor. For ambulatory care clinical pharmacists, managing dyslipidemia requires thorough command of the four statin benefit groups, quantitative 10-year cardiovascular risk calculators, non-statin add-on agents, triglyceride management pathways, and protocols for managing statin-associated muscle symptoms (SAMS).

---

Statin Therapy Intensity & Classification

Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are the cornerstone of lipid-lowering therapy, stabilizing atherosclerotic plaques, improving endothelial function, suppressing vascular inflammation, and lowering circulating LDL-C:

+-----------------------------------------------------------------------------+
|                        STATIN THERAPY INTENSITY LEVELS                      |
+-----------------------+-----------------------+-----------------------------+
| Intensity Level       | Expected LDL-C Lowering| Statin Agents & Daily Doses |
+-----------------------+-----------------------+-----------------------------+
| High-Intensity        | >= 50% Reduction      | Atorvastatin 40–80 mg       |
|                       |                       | Rosuvastatin 20–40 mg       |
+-----------------------+-----------------------+-----------------------------+
| Moderate-Intensity    | 30% to 49% Reduction  | Atorvastatin 10–20 mg       |
|                       |                       | Rosuvastatin 5–10 mg        |
|                       |                       | Simvastatin 20–40 mg        |
|                       |                       | Pravastatin 40–80 mg        |
|                       |                       | Lovastatin 40–80 mg         |
|                       |                       | Fluvastatin XL 80 mg        |
|                       |                       | Pitavastatin 1–4 mg         |
+-----------------------+-----------------------+-----------------------------+
| Low-Intensity         | < 30% Reduction       | Simvastatin 10 mg           |
|                       |                       | Pravastatin 10–20 mg        |
|                       |                       | Lovastatin 20 mg            |
|                       |                       | Fluvastatin 20–40 mg        |
+-----------------------+-----------------------+-----------------------------+

Note: Simvastatin 80 mg daily is not recommended for initiation due to significantly increased risk of myopathy and rhabdomyolysis.

---

The Four Primary Statin Benefit Groups

1. Secondary Prevention in Established Clinical ASCVD

• Definition of Clinical ASCVD: Acute coronary syndromes (ACS), history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) of atherosclerotic origin.
• Standard Therapy: High-intensity statin therapy to achieve $\ge 50%$ LDL-C reduction and LDL-C $<70\text{ mg/dL}$ (or $<55\text{ mg/dL}$ for very high-risk per recent ACC Expert Consensus pathways).
• Very High-Risk ASCVD Definition:
  • History of Multiple Major ASCVD Events: Recent ACS ($\le 12\text{ months}$), history of MI (other than recent ACS), history of ischemic stroke, or symptomatic PAD (claudication with $\text{ABI} <0.85$ or prior revascularization/amputation).
  • OR One Major ASCVD Event PLUS Multiple High-Risk Conditions: Diabetes mellitus, hypertension, CKD (eGFR 15–59 mL/min/1.73m²), current cigarette smoking, persistently elevated $\text{LDL-C} \ge 100\text{ mg/dL}$ despite maximally tolerated statin and ezetimibe, history of congestive heart failure, or age $\ge 65\text{ years}$.
• Stepwise Non-Statin Escalation in Very High-Risk:
  1. Maximize tolerated high-intensity statin.
  2. If on maximally tolerated statin and $\text{LDL-C} \ge 70\text{ mg/dL}$ (or non-HDL-C $\ge 100\text{ mg/dL}$), add Ezetimibe 10 mg daily.
  3. If on max statin + ezetimibe and $\text{LDL-C} \ge 70\text{ mg/dL}$, add a PCSK9 Inhibitor (Evolocumab or Alirocumab).

2. Severe Primary Hypercholesterolemia (Baseline LDL-C $\ge 190\text{ mg/dL}$)

• Risk Assessment: Do not calculate 10-year ASCVD risk; these patients have severe lifetime exposure (often Familial Hypercholesterolemia) and are automatically classified as high risk.
• Therapy: High-intensity statin to maximally tolerated dose.
• Target & Add-on: Aim for $\ge 50%$ LDL-C reduction and $\text{LDL-C} <100\text{ mg/dL}$. If LDL-C remains $\ge 100\text{ mg/dL}$ on maximally tolerated statin, add Ezetimibe 10 mg daily. If still $\ge 100\text{ mg/dL}$ and patient has baseline $\text{LDL-C} \ge 220\text{ mg/dL}$, add a PCSK9 inhibitor.

3. Diabetes Mellitus in Adults Age 40–75 (with LDL-C 70–189 mg/dL)

• Baseline Therapy: Moderate-intensity statin is indicated for all diabetic outpatients age 40–75 regardless of calculated 10-year risk.
• Upgrade to High-Intensity Statin: Indicated if patient has multiple ASCVD risk factors (e.g., long diabetes duration: $\ge 10\text{ years}$ for T2DM or $\ge 20\text{ years}$ for T1DM, albuminuria $\text{uACR} \ge 30\text{ mg/g}$, $\text{eGFR} <60\text{ mL/min}/1.73\text{m}^2$, diabetic retinopathy, neuropathy, or $\text{ABI} <0.9$) or calculated 10-year ASCVD risk $\ge 20%$.
• Target: Reduce LDL-C by 30% to 49% (moderate) or $\ge 50%$ (high). Adding ezetimibe is reasonable if 10-year risk $\ge 20%$ and LDL-C remains $\ge 70\text{ mg/dL}$.

4. Primary Prevention in Adults Age 40–75 (Without Diabetes, LDL-C 70–189 mg/dL)

Calculate the 10-year ASCVD risk using the Pooled Cohort Equations (PCE) or updated PREVENT equations:

• Low Risk ($<5%$): Emphasize lifestyle modifications alone; no statin indicated.
• Borderline Risk ($5%\text{ to }<7.5%$): Clinician-patient risk discussion. If risk-enhancing factors are present, consider moderate-intensity statin.
• Intermediate Risk ($7.5%\text{ to }<20%$): Initiate moderate-intensity statin targeting 30% to 49% LDL-C reduction if risk-enhancing factors are present.
• High Risk ($\ge 20%$): Initiate high-intensity statin targeting $\ge 50%$ LDL-C reduction.

Risk-Enhancing Factors

• Family history of premature ASCVD (males $<55\text{ years}$, females $<65\text{ years}$ in first-degree relatives)
• Persistently elevated $\text{LDL-C} \ge 160\text{ mg/dL}$
• Metabolic syndrome (increased waist circumference, elevated TG, low HDL, elevated BP, impaired fasting glucose)
• Chronic kidney disease (eGFR 15–59 mL/min/1.73m² not on dialysis)
• Chronic inflammatory conditions (Rheumatoid arthritis, SLE, psoriasis, HIV)
• History of premature menopause ($<40\text{ years}$) or pregnancy-associated conditions (preeclampsia)
• High-risk ethnicity (e.g., South Asian ancestry)
• Persistently elevated triglycerides (fasting $\text{TG} \ge 175\text{ mg/dL}$)
• High-sensitivity C-reactive protein ($\text{hs-CRP} \ge 2.0\text{ mg/L}$)
• Lipoprotein(a) [$\text{Lp(a)}$] $\ge 50\text{ mg/dL}$ (or $\ge 125\text{ nmol/L}$)
• Apolipoprotein B ($\text{ApoB} \ge 130\text{ mg/dL}$)
• Ankle-Brachial Index ($\text{ABI} <0.9$)

Coronary Artery Calcium (CAC) Scoring in Decision Uncertainty

In intermediate or borderline risk patients where the statin decision is uncertain:

• $\text{CAC} = 0\text{ Agatston units}$: Reassuring; safely withhold or delay statin therapy (unless patient is a current cigarette smoker, has diabetes, or strong family history of premature ASCVD). Re-evaluate in 5 years.
• $\text{CAC} = 1\text{ to }99\text{ units}$ (or $<75\text{th}$ percentile for age/sex): Favors statin initiation (especially age $\ge 55$).
• $\text{CAC} \ge 100\text{ units}$ (or $\ge 75\text{th}$ percentile): Statin therapy is strongly indicated; reclassifies patient to high risk.

---

Non-Statin Pharmacotherapy: Comparative Clinical Profiles

---

Hypertriglyceridemia Management Pathways

1. Moderate Hypertriglyceridemia (Fasting TG 150–499 mg/dL): Address lifestyle factors (low-fat diet, weight reduction, aerobic exercise, eliminate alcohol), optimize glycemic control in diabetes, and initiate/titrate statin therapy to target LDL-C.
2. Cardiovascular Risk Reduction with Icosapent Ethyl:
   • Icosapent Ethyl (IPE - Vascepa 2 g orally twice daily with meals = 4 g/day): Highly purified ethyl ester of eicosapentaenoic acid (EPA).
   • The REDUCE-IT Trial: In patients with established ASCVD or diabetes with $\ge 2$ risk factors who had fasting triglycerides between $135\text{ and }499\text{ mg/dL}$ on stable statin therapy, IPE 4 g/day produced a 25% relative risk reduction in MACE (composite CV death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina).
   • Adverse Effects & Precautions: Increased risk of atrial fibrillation/flutter (5.3% vs. 3.9%) and increased risk of minor bleeding (especially in patients on concomitant antiplatelets or anticoagulants).
   • Note: Mixed omega-3 supplements containing DHA (e.g., Lovaza) do not share these proven CV benefits (STRENGTH trial was negative) and DHA can increase LDL-C.
3. Severe Hypertriglyceridemia (Fasting TG $\ge 500\text{ mg/dL}$, especially $\ge 1,000\text{ mg/dL}$):
   • Primary Goal: Rapidly prevent acute pancreatitis.
   • First-Line Pharmacotherapy: Initiate Fenofibrate (48–145 mg daily) or prescription omega-3 fatty acids alongside a very low-fat diet ($<15%$ of total calories from fat), alcohol cessation, and glycemic optimization.
   • Fibrate Safety Pearl: Gemfibrozil is contraindicated with statins because it strongly inhibits statin glucuronidation (via OATP1B1 and CYP2C8), causing up to a 5-fold increase in statin concentrations and high risk of rhabdomyolysis. Fenofibrate does not significantly inhibit statin glucuronidation and is the fibrate of choice when combination therapy with a statin is required.

---

Statin Safety, Intolerance & SAMS Management

Statin-Associated Muscle Symptoms (SAMS)

• Myalgia: Muscle aches, weakness, or stiffness without significant serum Creatine Kinase (CK) elevation (reported in 5% to 10% of clinical practice).
• Myositis / Myopathy: Muscle symptoms accompanied by CK elevation ($>10\times\text{ Upper Limit of Normal [ULN]}$).
• Rhabdomyolysis: Severe muscle necrosis with $\text{CK} >40\times\text{ ULN}$, myoglobinuria (brown urine), and acute renal failure (extremely rare, $<0.1%$).
• Risk Factors: Advanced age ($>75\text{ years}$), female sex, low BMI, renal/hepatic dysfunction, untreated hypothyroidism, vitamin D deficiency, high-dose statins, and CYP3A4-inhibiting drug interactions (e.g., clarithromycin, ketoconazole, protease inhibitors, diltiazem, verapamil, amiodarone, grapefruit juice with simvastatin, lovastatin, or atorvastatin).

SAMS Structured Management Protocol

+-----------------------------------------------------------------------------+
|                     SAMS STEPWISE RECHALLENGE PROTOCOL                      |
+-----------------------------------------------------------------------------+
| Step 1: Discontinue statin for a 2- to 4-week washout period until muscle   |
|         symptoms completely resolve. Check baseline CK, TSH, and Vitamin D. |
+-----------------------------------------------------------------------------+
| Step 2: Rechallenge with the same statin at a lower dose OR switch to a     |
|         pharmacokinetically distinct hydrophilic statin (Rosuvastatin or    |
|         Pravastatin) rather than lipophilic statins (Simvastatin/Atorvastatin)
+-----------------------------------------------------------------------------+
| Step 3: If daily dosing fails, utilize non-daily alternative dosing:        |
|         Rosuvastatin (5–10 mg) or Atorvastatin (10–20 mg) dosed 2 to 3 times|
|         weekly or every other day (leveraging their long 19-hr half-lives).  |
+-----------------------------------------------------------------------------+
| Step 4: If true statin intolerance persists across >= 2-3 statins at minimal|
|         doses, initiate non-statin therapy with Ezetimibe + Bempedoic Acid  |
|         (which does not enter skeletal muscle) and/or a PCSK9 Inhibitor.    |
+-----------------------------------------------------------------------------+

Liver and Glycemic Safety

• Hepatic Safety: Baseline ALT/AST measurement is recommended prior to statin initiation. Routine periodic liver enzyme monitoring is no longer recommended unless symptoms of hepatotoxicity occur (jaundice, dark urine, RUQ abdominal pain). Asymptomatic transaminase elevations $<3\times\text{ ULN}$ are benign and do not warrant statin discontinuation.
• New-Onset Diabetes Risk: Statins can produce a modest dose-dependent increase in HbA1c (typically 0.1% to 0.3%), primarily in patients with pre-existing metabolic syndrome or prediabetes. The absolute cardiovascular benefit of statin therapy vastly outweighs the modest risk of dysglycemia; statins should never be discontinued due to mild A1c increases.